Neoadjuvant-intensified treatment for rectal cancer: Time to change?

Table 1 Characteristics of patients n (%)

Characteristics	Patients
Performance status
0	52 (65.00)
1	27 (33.75)
2	1 (1.25)
Localization
≤ 5 cm from anal verge	45 (56.25)
> 5 to ≤ 8 cm from anal verge	19 (23.75)
> 8 cm from anal verge	16 (20.00)
Stage
IIA	19 (23.75)
IIIA	1 (1.25)
IIIB	30 (37.50)
IIIC	30 (37.50)

Table 2 Evaluation of overall survival and disease-free survival

Cohort	α	Ω	AP, mo	OS, mo	DFS, mo	OS/AP %	DFS/OS %
2007	16	3	54.00	50.90	46.90	94.28	92.14
2008	22	3	42.90	39.30	34.90	91.40	89.01
2009	18	2	30.80	29.40	22.60	95.53	76.97
2010	13	0	17.40	17.40	15.30	100.00	87.93
2011	11	0	6.30	6.30	5.60	100.00	88.79
Total	80	8	29.80	27.90	23.90	93.45	85.88

α: Survived; Ω: Died; AP: Absolute permanence; OS: Overall survival; DFS: Disease-free survival.

Table 3 Incidence of acute toxicity n (%)

	G1	G2	G3
Blood-bone marrow
Neutrofilis-granulocytes	1 (1.25)
Allergy-immunology
Allergic reaction-hypersensitivity	6 (7.5)
Cardiac arrhythmia
Palpitation	1 (1.25)
Constitutional symptoms
Fatigue	10 (12.5)	5 (6.25)
Fever	7 (8.75)	1 (1.25)
Dermatology-skin
Pruritus-itching	2 (2.5)
Rash-desquamation	2 (2.5)	6 (7.5)
Radiation-dermatitis	10 (12.5)	17 (21.25)	3 (3.75)
Gastrointestinal
Constipation	2 (2.5)	15 (18.75)
Diarrhea	14 (17.5)	11 (13.75)	3 (3.75)
Nausea	12 (15)
Proctitis	6 (7.5)	51 (63.75)	4 (5)
Vomiting	5 (6.25)	1 (1.25)
Neurology
Neuropathy: sensory	14 (17.5)	1 (1.25)	1 (1.25)
Pain
Pelvic pain	1 (1.25)	3 (3.75)
Abdominal pain or cramping	6 (7.5)	2 (2.5)	2 (2.5)
Renal-genitourinary
Dysuria-painful urination	12 (15)	11 (13.75)
Urinary frequency	3 (3.75)
	G3	G4	G5
Cardiovascular
Vascular thromboembolism	7 (8.75)	2 (2.5)	2 (2.5)